China Business Law Journal (CBLJ) has recognized Sidley for 13 “Deals of the Year” for 2024. Each year, CBLJ reviews the standout deals of the prior year, considering the “overall significance, complexity, innovative nature and deal size” of matters.
CBLJ has identified the following Sidley matters as “Deals of the Year”:
- Chinese EV companies defense against EU subsidies probe
- D3 Bio's US$40 million series A+ financing
- Evergrande's debt restructuring
- Hengrui's out-licenses GLP-1 to Hercules
- Kaisa's offshore debt restructuring
- Shang Gong’s stalking horse bid for ICON
- Shanghai Pharma's collaboration with Sanofi Aventis
- Shimao Group's debt restructuring
- Sunac’s US$10.2 billion offshore restructuring
- Tsinghua Unigroup's ups stake in H3C
- XtalPi (QuantumPharm)’s Hong Kong IPO
- Zeekr’s US$441 million NYSE IPO
- Zhongliang Holdings' debt restructuring